



COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1150
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/648,139	08/26/2003	Jason M. Johnson	RS0204Y

R. Douglas Bradley
Merck & Co., Inc.
Patent Department RY60-30
P.O. Box 2000
Rahway, NJ 07065-0907

CONFIRMATION NO. 3611

FORMALITIES LETTER



OC000000011307572

Date Mailed: 11/19/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, appearing to read "M. J. Smith", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



SEP
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Johnson, Jason M. et al.

Serial No.: US 10/648,139

Art Unit: To Be Assigned

Case No.: RS0204Y

Filed: August 26, 2003

Examiner: To Be Assigned

For: Alternatively Spliced Isoforms of
Human PHKA2

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENT FOR PATENT
APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES

Kirkland, Washington 98034

08 December 2003

Sir:

In response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed November
19, 2003, enclosed herewith are:

- 1) A substitute Computer Readable Form of the Replacement Sequence Listing;
- 2) A paper copy of the Replacement Sequence Listing that is an identical copy of the
Replacement Sequence Listing on the Computer Readable Form;
- 3) An Amendment directing entry of the Replacement Sequence Listing into the
specification; and

Serial No.: ,

Case No.:

4) A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures that was mailed to Applicants on November 19, 2003.

The replacement Computer Readable Form is a Diskette with the Sequence Listing described as follows:


Diskette:

Machine Format: IBM-PC/XP
Operating System: MS-Windows XP Professional
File Name: PHKA2.ST25.TXT
File Format: ASCII
Size: 54,393bytes
Creation Date: 05 December 2003.

I hereby state that the sequence listing information recorded in computer readable form is identical to the paper copy of the replacement sequence listing submitted herewith.

Please charge deposit account number 502287 for any fees due in connection with this Response to Notice to Comply. If any time extensions are needed for the timely filing of the present response, applicants petition for such extensions and authorize the charging of deposit account number 502287 for the appropriate fees.

Respectfully submitted,
ROSETTA INPHARMATICS LLC



R. Douglas Bradley
Reg. No. 44,553
Rosetta Inpharmatics LLC
12040-115th Avenue NE
Kirkland, WA 98034
Direct Dial No. 425-636-6301

